Lexicon
Sep 12, 2019
Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership
Mallinckrodt has announced to sell its Canadian drug manufacturing BioVectra Inc. to a Miami-based private equity firm, an affiliate of H.I.G. Capital for approximately USD 250 Million. The agreement included a fixed amount of USD 175 Million, with an upfront amount of USD 135 Million, a long term payment of US...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
